Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 13Thoracic 3Gastrointestinal 2Sarcoma 1NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Gliosarcoma 22Glioblastoma 22Brain Neoplasms 16Glioma 10Astrocytoma 9Oligodendroglioma 8Central Nervous System Neoplasms 7Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Medulloblastoma 2Gastrointestinal Stromal Tumors 2Esthesioneuroblastoma, Olfactory 2Esophageal Neoplasms 2Ependymoma 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

Cyclophosphamide 7pembrolizumab 6Radiosurgery 6Specimen Handling 5Nivolumab 5Ifosfamide 5fludarabine phosphate 4Mycophenolic Acid 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Busulfan 4Sunitinib 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Melphalan 3Magnetic Resonance Spectroscopy 3Filgrastim 3Cyclosporine 3Cryosurgery 3Carboplatin 3trastuzumab deruxtecan 2tislelizumab 2sargramostim 2pazopanib 2fludarabine 2etoposide phosphate 2cabozantinib 2Whole-Body Irradiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Erlotinib Hydrochloride × Sarcoma × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡